COVID-19 vaccine: NTAGI to review Covovax data for use in kids aged 12 years and above
India's drug regulator had approved Covovax for restricted use in emergency situations in adults on 28th December, 2021, and those…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
New cancer immunotherapy fails in first Roche trial
The Skyscraper-II trial was the first to produce results in the final stage of clinical testing in a class of drugs known as…
GE Healthcare announces first patient dosed in phase-III clinical trial for new dopamine transporter…
Next-stage clinical study also proceeding for SPECT radiopharma
Sun Pharma to introduce its version of Vortioxetine in India
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in…
Sanofi and IGM Biosciences announce collaboration agreement for oncology, immunology and…
Collaboration to create, develop, manufacture and commercialise new class of potential therapeutics combining the superior…
US FDA approves Novo Nordisk’s Ozempic 2 mg to treat type-II diabetes
Ozempic demonstrated 2.1 per cent blood sugar reduction and also weight loss in adults with type-II diabetes with new 2 mg dose
Health minister says local manufacturing of 35 APIs started after PLI scheme
This would lead to reduction in import dependence of the key raw materials used for producing medicines, said the minister
ICMR study has shown rise in antibodies post Covaxin booster dose: MoS Health tells RS
International data available on booster doses of AstraZeneca and Covishield suggests a three-to four-fold increase in antibody…
Data required for suggesting mixing of COVID-19 vaccine: Government
CDSCO has granted permission to CMC, Vellore, to conduct phase-IV study with Covishield and Covaxin to compare immunogenicity of…
ASPA releases report on substandard and falsified medical products during COVID-19
The report highlights the trends in pharma crime and incidents of sub-standard and falsified (SF) medical products during COVID-19…